This is a preprint.
Thoracic Aortic Three-Dimensional Geometry
- PMID: 38798566
- PMCID: PMC11118285
- DOI: 10.1101/2024.05.09.593413
Thoracic Aortic Three-Dimensional Geometry
Update in
-
Thoracic Aortic Three-Dimensional Geometry.Pulse (Basel). 2025 Jan 27;13(1):72-79. doi: 10.1159/000543613. eCollection 2025 Jan-Dec. Pulse (Basel). 2025. PMID: 40330437
Abstract
Background: Aortic structure impacts cardiovascular health through multiple mechanisms. Aortic structural degeneration occurs with aging, increasing left ventricular afterload and promoting increased arterial pulsatility and target organ damage. Despite the impact of aortic structure on cardiovascular health, three-dimensional (3D) aortic geometry has not been comprehensively characterized in large populations.
Methods: We segmented the complete thoracic aorta using a deep learning architecture and used morphological image operations to extract multiple aortic geometric phenotypes (AGPs, including diameter, length, curvature, and tortuosity) across various subsegments of the thoracic aorta. We deployed our segmentation approach on imaging scans from 54,241 participants in the UK Biobank and 8,456 participants in the Penn Medicine Biobank.
Conclusion: Our method provides a fully automated approach towards quantifying the three-dimensional structural parameters of the aorta. This approach expands the available phenotypes in two large representative biobanks and will allow large-scale studies to elucidate the biology and clinical consequences of aortic degeneration related to aging and disease states.
Keywords: 3D aortic structure; Deep learning; UK Biobank.
Conflict of interest statement
(1) Dr. Chirinos is supported by NIH grants U01-TR003734, U01-TR003734-01S1, UO1-HL160277, R33-HL-146390, R01-HL153646, K24-AG070459, R01-AG058969, R01-HL157108, R01-HL155599, R01-HL104106 and R01HL155764. He has recently consulted for Bayer, Fukuda-Denshi, Bristol-Myers Squibb, Biohaven Pharmaceuticals, Johnson & Johnson, Edwards Life Sciences, Merck, and NGM Biopharmaceuticals. He received University of Pennsylvania research grants from National Institutes of Health, Fukuda-Denshi, Bristol-Myers Squibb, Microsoft and Abbott. He is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of Heart Failure and Preserved Ejection Fraction and for the use of biomarkers in heart failure with preserved ejection fraction. He has received payments for editorial roles from the American Heart Association, the American College of Cardiology, Elsevier and Wiley, and payments for academic roles from the University of Texas, Boston University, and Virginia Commonwealth University. He has received research device loans from Atcor Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft and MicroVision Medical. (2) The remaining authors have nothing to disclose.
Figures
References
Publication types
Grants and funding
- R01 HL137984/HL/NHLBI NIH HHS/United States
- R01 HL155599/HL/NHLBI NIH HHS/United States
- UL1 TR001878/TR/NCATS NIH HHS/United States
- R03 HL146874/HL/NHLBI NIH HHS/United States
- R01 HL104106/HL/NHLBI NIH HHS/United States
- R01 HL121510/HL/NHLBI NIH HHS/United States
- R56 HL136730/HL/NHLBI NIH HHS/United States
- R01 AG058969/AG/NIA NIH HHS/United States
- R01 HL153646/HL/NHLBI NIH HHS/United States
- R33 HL146390/HL/NHLBI NIH HHS/United States
- R01 EB031722/EB/NIBIB NIH HHS/United States
- R01 HL133889/HL/NHLBI NIH HHS/United States
- R01 HL155764/HL/NHLBI NIH HHS/United States
- U01 TR003734/TR/NCATS NIH HHS/United States
- P01 HL094307/HL/NHLBI NIH HHS/United States
- R01 HL157108/HL/NHLBI NIH HHS/United States
- P41 EB029460/EB/NIBIB NIH HHS/United States
- K24 AG070459/AG/NIA NIH HHS/United States
- R01 HL169378/HL/NHLBI NIH HHS/United States
- U01 HL160277/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources